Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers report. The aptamers -- short ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that ...

Moleculin Biotech has begun dosing subjects in a Phase III trial of Annamycin with Cytarabine for treating acute myeloid ...

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified a promising new drug target for acute myeloid leukemia (AML), a deadly ...

Research subjects include neuroblastoma, Ewing's sarcoma and other common solid tumors, and childhood leukemia, especially acute lymphoblastic leukemia. The content of the article may cover the immune ...

AML: Acute myeloid leukemia; CLL: C-type lectin-like molecule; CXCR: CXC chemokine receptor; N/A: Not applicable; NF: Nuclear factor. Acute myeloid leukemia (AML) remains incurable for the ...

Leukemia is a broad term; there are actually several different types of this condition. It can be “acute — sudden onset” or “chronic — slow onset.” Leukemia is a blood cancer.

Further, compared to insulin use, GLP-1RA use was associated with a significantly reduced risk of lymphoid leukemia, myeloid leukemia, MPN, MDS, amyloidosis, non-Hodgkin lymphoma, monoclonal ...